{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:45:54Z","timestamp":1790635554128,"version":"4.1.0"},"reference-count":67,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"University of Arizona, Division of Hematology and Medical Oncology"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a heterogeneous group of malignancies characterized by varying degrees of aggressiveness and clinical behavior. Despite advancements in treatment, including targeted therapies such as sunitinib and everolimus, peptide receptor radionuclide therapy with [177Lu]Lu-DOTATATE, and chemotherapy regimens like capecitabine plus temozolomide, the advanced GEP-NETs remain largely incurable. The limited efficacy of current treatments highlights the urgent need for novel therapeutic strategies. Recent years have seen a rise in several landmark clinical trials aimed at exploring new agents and combinations to improve patient outcomes in GEP-NETs. This literature review focuses on the ongoing clinical trials that hold promise for advancing the treatment landscape of GEP-NETs. We include some industry- and cooperative group-sponsored, phase II-III, randomized, and comparative trials in our review. We analyze the design, rationale, objectives, and preliminary findings of these trials, with a particular emphasis on those with pending results that may offer new insights into potential therapeutic targets. By examining these trials, we aim to provide a comprehensive overview of the evolving strategies in the management of GEP-NETs and underscore the importance of continued research innovation in addressing the challenges posed by the heterogeneity of GEP-NETs and in the pursuit of more effective and potentially curative treatment options.<\/jats:p>","DOI":"10.3390\/jcm14186522","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T08:03:47Z","timestamp":1758096227000},"page":"6522","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Current Clinical Trial Landscape of Gastroenteropancreatic Neuroendocrine Tumors: A New Era of Landmark Trials"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3895-9474","authenticated-orcid":false,"given":"Supriya","family":"Peshin","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Norton Community Hospital, Norton, VA 24273, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0406-0281","authenticated-orcid":false,"given":"Shivani","family":"Modi","sequence":"additional","affiliation":[{"name":"Jefferson Health, Einstein Healthcare Network, Philadelphia, PA 19141, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrick","family":"Babakhanlou","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, University of Arizona, Tucson, AZ 85719, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6576-3971","authenticated-orcid":false,"given":"Junaid","family":"Arshad","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, University of Arizona, Tucson, AZ 85719, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1210\/endrev\/bnz004","article-title":"Advances in the diagnosis and management of well-differentiated neuroendocrine neoplasms","volume":"41","author":"Hofland","year":"2020","journal-title":"Endocr. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1159\/000503721","article-title":"Neuroendocrine neoplasms of the small bowel and pancreas","volume":"110","author":"Clift","year":"2020","journal-title":"Neuroendocrinology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.neo.2017.09.002","article-title":"Nothing but NET: A review of neuroendocrine tumors and carcinomas","volume":"19","author":"Oronsky","year":"2017","journal-title":"Neoplasia"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1159\/000512089","article-title":"Neuroendocrine tumors of the gastrointestinal tract: A focused review and practical approach for gastroenterologists","volume":"28","year":"2021","journal-title":"GE Port. J. Gastroenterol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201ccarcinoid\u201d: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/17446651.2023.2279540","article-title":"Current understanding of pathogenetic mechanisms in neuroendocrine neoplasms","volume":"19","author":"Modica","year":"2024","journal-title":"Expert Rev. Endocrinol. Metab."},{"key":"ref_7","first-page":"471","article-title":"Gastroenteropancreatic Neuroendocrine Tumors","volume":"68","author":"Cives","year":"2018","journal-title":"CA A Cancer J. Clin."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Cives, M., Pelle\u2019, E., and Strosberg, J. (2020). Emerging treatment options for gastroenteropancreatic neuroendocrine tumors. J. Clin. Med., 9.","DOI":"10.3390\/jcm9113655"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1172\/JCI67963","article-title":"The genomic landscape of small intestine neuroendocrine tumors","volume":"123","author":"Banck","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Wu, R., Chen, S., He, Y., Li, Y., Mu, S., and Jin, A. (2025). Machine learning based predictive model and genetic mutation landscape for high-grade colorectal neuroendocrine carcinoma: A SEER database analysis with external validation. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1509170"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1006\/frne.1999.0183","article-title":"Somatostatin and its receptor family","volume":"20","author":"Patel","year":"1999","journal-title":"Front. Neuroendocrinol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"822","DOI":"10.2741\/2722","article-title":"Molecular mechanisms of the antiproliferative activity of somatostatin receptors (SSTRs) in neuroendocrine tumors","volume":"13","author":"Florio","year":"2008","journal-title":"Front. Biosci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","article-title":"Overview of the 2022 WHO classification of neuroendocrine neoplasms","volume":"33","author":"Rindi","year":"2022","journal-title":"Endocr. Pathol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.coemr.2021.04.007","article-title":"Functioning and nonfunctioning pNENs","volume":"18","author":"Daskalakis","year":"2021","journal-title":"Curr. Opin. Endocr. Metab. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"9512","DOI":"10.3748\/wjg.v21.i32.9512","article-title":"Non-functional neuroendocrine tumors of the pancreas: Advances in diagnosis and management","volume":"21","author":"Cloyd","year":"2015","journal-title":"World J. Gastroenterol. WJG"},{"key":"ref_16","first-page":"e44718","article-title":"Early definitive diagnosis and management of incidental neuroendocrine tumors found on gastrointestinal endoscopy","volume":"15","author":"Somnay","year":"2023","journal-title":"Cur\u0113us"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"791","DOI":"10.4251\/wjgo.v12.i8.791","article-title":"Gastrointestinal neuroendocrine tumors in 2020","volume":"12","author":"Ahmed","year":"2020","journal-title":"World J. Gastrointest. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.kjms.2018.05.009","article-title":"Prognostic factors of patients with gastroenteropancreatic neuroendocrine neoplasms","volume":"34","author":"Huang","year":"2018","journal-title":"Kaohsiung J. Med. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1159\/000513249","article-title":"Unique metastatic patterns in neuroendocrine neoplasms of different primary origin","volume":"111","author":"Hermans","year":"2021","journal-title":"Neuroendocrinology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.surg.2016.05.055","article-title":"Identification of primary tumors in patients presenting with metastatic gastroenteropancreatic neuroendocrine tumors","volume":"161","author":"Keck","year":"2017","journal-title":"Surgery"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1126\/science.1200609","article-title":"DAXX\/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors","volume":"331","author":"Jiao","year":"2011","journal-title":"Science"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/oncolo\/oyac049","article-title":"Survival and incidence patterns of pancreatic neuroendocrine tumors over the last two decades: A SEER database analysis","volume":"27","author":"Sonbol","year":"2022","journal-title":"Oncologist"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1159\/000197899","article-title":"Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the Mid-Gut","volume":"89","author":"Strosberg","year":"2009","journal-title":"Neuroendocrinology"},{"key":"ref_24","first-page":"968","article-title":"ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site","volume":"387","author":"Pavel","year":"2016","journal-title":"Lancet"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.yfrne.2013.07.005","article-title":"Somatostatin receptors: From signaling to clinical practice","volume":"34","author":"Theodoropoulou","year":"2013","journal-title":"Front. Neuroendocrinol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000443612","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): Results of long-term survival","volume":"104","author":"Rinke","year":"2017","journal-title":"Neuroendocrinology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1200\/jco.2016.34.4_suppl.434","article-title":"Tumor response in the CLARINET study of lanreotide depot vs. placebo in patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs)","volume":"34","author":"Phan","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1200\/JCO.2016.68.0702","article-title":"Everolimus for the treatment of advanced pancreatic neuroendocrine tumors: Overall survival and circulating biomarkers from the randomized, phase III RADIANT-3 Study","volume":"34","author":"Yao","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): A randomised, placebo-controlled, phase 3 study","volume":"387","author":"Yao","year":"2016","journal-title":"Lancet"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1200\/JCO.22.01013","article-title":"Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients with Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211)","volume":"41","author":"Kunz","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","article-title":"[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): An open-label, randomised, phase 3 study","volume":"403","author":"Singh","year":"2024","journal-title":"Lancet."},{"key":"ref_32","first-page":"222","article-title":"Practice guideline neuroendocrine tumors\u2014AWMF-Reg. 021-27","volume":"32","author":"Rinke","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.1200\/JCO.23.01529","article-title":"Systemic therapy for tumor control in metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: ASCO Guideline","volume":"41","author":"Perez","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"5943","DOI":"10.1158\/1078-0432.CCR-20-1804","article-title":"Comprehensive genomic profiling of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs)","volume":"26","author":"Puccini","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Chauhan, A., Del Rivero, J., Ramirez, R.A., Soares, H.P., and Li, D. (2022). Treatment sequencing strategies in advanced neuroendocrine tumors: A review. Cancers, 14.","DOI":"10.3390\/cancers14215248"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000443171","article-title":"ENETS Consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors","volume":"103","author":"Falconi","year":"2016","journal-title":"Neuroendocrinology"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Akirov, A., Larouche, V., Alshehri, S., Asa, S.L., and Ezzat, S. (2019). Treatment options for pancreatic neuroendocrine tumors. Cancers, 11.","DOI":"10.3390\/cancers11060828"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/s41574-018-0082-5","article-title":"Role of Biomarker Tests for Diagnosis of Neuroendocrine Tumours","volume":"14","author":"Hofland","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1055\/s-0031-1287794","article-title":"Biomarkers and Molecular Imaging in Gastroenteropancreatic Neuroendocrine Tumors","volume":"43","author":"Lindholm","year":"2011","journal-title":"Horm. Metab. Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/j.annonc.2021.08.1746","article-title":"A Multigenomic Liquid Biopsy Biomarker for Neuroendocrine Tumor Disease Outperforms CgA and Has Surgical and Clinical Utility","volume":"32","author":"Modlin","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"101785","DOI":"10.1016\/j.beem.2023.101785","article-title":"Established and Novel Circulating Neuroendocrine Tumor Biomarkers for Diagnostic, Predictive and Prognostic Use","volume":"37","author":"Tsoli","year":"2023","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Komarnicki, P., Musia\u0142kiewicz, J., Sta\u0144ska, A., Maciejewski, A., Gut, P., Mastorakos, G., and Rucha\u0142a, M. (2022). Circulating Neuroendocrine Tumor Biomarkers: Past, Present and Future. J. Clin. Med., 11.","DOI":"10.3390\/jcm11195542"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"R157","DOI":"10.1530\/ERC-18-0354","article-title":"Neuroendocrine Neoplasms: Current and Potential Diagnostic, Predictive and Prognostic Markers","volume":"26","author":"Hofland","year":"2019","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","article-title":"177 Lu-dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): Final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial","volume":"22","author":"Strosberg","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.2967\/jnumed.112.119347","article-title":"Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate","volume":"54","author":"Sabet","year":"2013","journal-title":"J. Nucl. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"4132","DOI":"10.1200\/JCO.2023.41.16_suppl.4132","article-title":"ACTION-1 phase Ib\/3 trial of RYZ101 in somatostatin receptor subtype 2\u2013expressing (SSTR2+) gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177 Lu somatostatin analogue (SSA) therapy: Initial safety analysis","volume":"41","author":"Morris","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1007\/s00259-019-04567-2","article-title":"Broadening horizons with 225Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to 177Lu-DOTATATE PRRT: First clinical experience on the efficacy and safety","volume":"47","author":"Ballal","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"4020","DOI":"10.1200\/JCO.2024.42.16_suppl.4020","article-title":"Safety, tolerability and efficacy of 212 Pb-Dotamtate as a targeted alpha therapy for subjects with unresectable or metastatic somatostatin receptor-expressing gastroenteropancreatic neuroendocrine tumors (SSTR+ GEP-NETs): A phase 2 study","volume":"42","author":"Strosberg","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_50","first-page":"T11","article-title":"NET RETREAT: A Phase II Study of 177Lutetium-Dotatate Retreatment vs. Everolimus in Metastatic\/Unresectable Midgut NET","volume":"98","author":"Chauhan","year":"2023","journal-title":"Endocr. Abstr."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"VIII478","DOI":"10.1093\/annonc\/mdy293.028","article-title":"1335\u2014TiP\u2014COMPETE trial: Peptide receptor radionuclide therapy (PRRT) with 177Lu-edotreotide vs. everolimus in progressive GEP-NET","volume":"29","author":"Pavel","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Halfdanarson, T.R., Reidy, D., Vijayvergia, N., Halperin, D., Goldstein, G., Kong, G., Michael, M., Leyden, S., Grozinsky-Glasberg, S., and Sorbye, H. (2024, November 01). Compose: Pivotal Phase III Trial of 177LuEdotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade 2 and Grade 3 Gastroenteropancreatic Neuroendocrine Tumors. Available online: https:\/\/nanets.net\/abstracts-archive\/2021-1\/1606-nanets-2021-abstracts-c30-compose-pivotal-phase-iii-trial-of-177lu-edotreotide-versus-best-standard-of-care-in-well-differentiated-aggressive-grade-2-and-grade-3-gastroenteropancreatic\/file.","DOI":"10.1200\/JCO.2022.40.4_suppl.TPS514"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"TPS658","DOI":"10.1200\/JCO.2023.41.4_suppl.TPS658","article-title":"ETCTN 10450: A phase I trial of peposertib and lutetium 177 DOTATATE in well-differentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs)","volume":"41","author":"Chauhan","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"TPS4660","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS4660","article-title":"Etctn 10388: A phase I trial of triapine and lutetium Lu 177 dotatate in well-differentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs)","volume":"38","author":"Chauhan","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2967\/jnumed.124.268902","article-title":"177 Lu-DOTATATE in Combination with PARP Inhibitor Olaparib Is Feasible in Patients with Somatostatin-Positive Tumors: Results from the LuPARP Phase I Trial","volume":"66","author":"Hallqvist","year":"2025","journal-title":"J. Nucl. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"940","DOI":"10.7150\/thno.91268","article-title":"Peptide receptor radionuclide therapy combinations for neuroendocrine tumours in ongoing clinical trials: Status 2023","volume":"14","author":"Santo","year":"2024","journal-title":"Theranostics"},{"key":"ref_57","first-page":"TPS672","article-title":"A first-in-human phase I trial with antibody drug conjugate ADCT-701 in neuroendocrine tumors and carcinomas","volume":"43","author":"Glod","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1056\/NEJMoa2403991","article-title":"Cabozantinib in Advanced Neuroendocrine Tumors","volume":"392","author":"Chan","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1200\/JCO.2025.43.4_suppl.666","article-title":"Efficacy and safety of cabozantinib for advanced gastrointestinal (GI) neuroendocrine tumors (NET) after progression on prior therapy: Subgroup analysis of the phase 3 CABINET trial (Alliance A021602)","volume":"43","author":"Strosberg","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"TPS515","DOI":"10.1200\/JCO.2022.40.4_suppl.TPS515","article-title":"Randomized phase II trial of postoperative adjuvant capecitabine and temozolomide versus observation in high-risk pancreatic neuroendocrine tumors: SWOG 2104","volume":"40","author":"Soares","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"17588359211018047","DOI":"10.1177\/17588359211018047","article-title":"Novel therapeutics for patients with well-differentiated gastroenteropancreatic neuroendocrine tumors","volume":"13","author":"Das","year":"2021","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"4110","DOI":"10.1200\/JCO.2021.39.15_suppl.4110","article-title":"The safety and efficacy of PEN-221 somatostatin analog (SSA)-DM1 conjugate in patients (PTS) with advanced GI mid-gut neuroendocrine tumor (NET): Phase 2 results","volume":"39","author":"Halperin","year":"2021","journal-title":"J. Clin Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1080\/08998280.2023.2284039","article-title":"Resistant gastroenteropancreatic neuroendocrine tumors: A definition and guideline to medical and surgical management","volume":"37","author":"Davis","year":"2024","journal-title":"Proc. Bayl. Univ. Med. Cent."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1080\/17446651.2022.2099840","article-title":"Therapeutic strategies for patients with neuroendocrine neoplasms: Current perspectives","volume":"17","author":"Modica","year":"2022","journal-title":"Expert Rev. Endocrinol. Metabol."},{"key":"ref_67","first-page":"1511","article-title":"Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience","volume":"120","author":"Fine","year":"2014","journal-title":"Cancer"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/18\/6522\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:46:50Z","timestamp":1760035610000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/18\/6522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,17]]},"references-count":67,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["jcm14186522"],"URL":"https:\/\/doi.org\/10.3390\/jcm14186522","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,17]]}}}